Facebook icon Twitter icon Forward icon

Diabetes service achieves 'seamless approach'

A “revolutionary” single integrated diabetes service across primary, community and hospital services has helped create a more “seamless” approach to patient care.

The initiative was recognised and won at last year’s Quality in Care (QiC) awards in the addressing unacceptable variation category. To read more, click here.

Type 2 drug could lower breast cancer risk

Metformin, the drug commonly used to treat type 2 diabetes, could help significantly reduce the risk of breast cancer.

Research carried out by the University of Copenhagen has suggested that women with diabetes using the drug were 40 per cent less likely to have dense breast tissue.

The study, which researchers say is the first to look at the impact of diabetes treatments on breast density, was unveiled at the European Breast Cancer Conference. To read more, click here.

Type 2 drug does not increase heart events

Dulaglutide does not increase the risk of major cardiovascular (CV) events in people with type 2 diabetes, research has found.

The meta-analysis evaluated the CV risk in people with the condition who were treated with Dulaglutide in nine randomised safety and efficacy trials. To read more, click here

New system joins up diabetes health records

Patient diabetes records are being shared between healthcare trusts and healthcare professionals seamlessly in Northern Ireland, as a result of new technology.

Interfaces have enabled the Northern Ireland Electronic Care Record (NIECR), to be populated with diabetes data. To read more, click here.

Ninjabetic - Transitional care therapy

Transitional care, eh. What’s that all about?

I’ve been presenting about it, reading about it and listening to discussions about it for the last few weeks and I have to admit, I’m feeling slightly envious of transition services.

There. I said it. I’m silly, but I’m jealous of a service. To read more, click here